Rosalind Advisors’s Verona Pharma VRNA Stock Holding History

Rosalind Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$10.7M	–	47
2025 Q3	$10.7M	Hold	100,000	–	–	3.65%	11
2025 Q2	$9.46M	Hold	100,000	–	–	4.48%	8
2025 Q1	$6.35M	Sell	100,000 -50,000	-33%	-$2.99M	3.09%	14
2024 Q4	$6.97M	Sell	150,000 -125,000	-45%	-$4.69M	3.56%	12
2024 Q3	$7.91M	Buy	275,000 +25,000	+10%	+$615K	5.07%	8
2024 Q2	$3.62M	Hold	250,000	–	–	2.78%	17
2024 Q1	$4.02M	Hold	250,000	–	–	3.76%	12
2023 Q4	$4.97M	Buy	+250,000	New	+$3.69M	4.09%	12

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Rosalind Advisors's VRNA Position: Q4 2025 in Review

Rosalind Advisors sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 100,000 shares — an estimated $10.7M sold.

Rosalind Advisors first reported a position in VRNA in Q4 2023 and held it in 8 quarters. The position peaked at $10.7M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Rosalind Advisors reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Rosalind Advisors sold 100,000 Verona Pharma shares in Q4 2025, an estimated $10.7M.
Rosalind Advisors first reported a position in Verona Pharma in Q4 2023 and held it in 8 quarters.
Rosalind Advisors's Verona Pharma position peaked at $10.7M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Rosalind Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.